<div id="readability-page-1"><div><p><span></span></p><ul><li>Carisma Therapeutics Inc   is expected to  show a fall in quarterly revenue when it reports  results on November 5 (estimated) for the period ending September 30 2025</li><li></li><li>​LSEG's mean analyst estimate for Carisma Therapeutics Inc is for a loss of 12 cents per share. </li><li>The current average analyst rating on the shares is &#34;buy&#34; and the breakdown of recommendations is 1 &#34;strong buy&#34; or &#34;buy,&#34; 1 &#34;hold&#34; and no &#34;sell&#34; or &#34;strong sell.&#34;  </li><li>The mean earnings estimate of analysts was unchanged in the last three months. ​</li><li>Wall Street's median 12-month price target for Carisma Therapeutics Inc is $1.00, about 94.4% above its last closing price of $0.06</li></ul></div></div>

CARM

<p>Carisma Therapeutics Inc is anticipated to report a loss of 12 cents per share for the quarter ending September 30, 2025, with results expected on November 5. Analysts maintain a "buy" rating, with one strong buy, one hold, and no sell recommendations. The median 12-month price target is $1.00, representing a potential increase of 94.4% from the last closing price of $0.06.</p>

Carisma Therapeutics Inc expected to post a loss of 12 cents a share - Earnings Preview